A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer
- 30 September 2014
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 20 (19), 5009-5022
- https://doi.org/10.1158/1078-0432.ccr-14-1122-t
Abstract
Purpose: Epstein–Barr virus (EBV) is associated with several cancers in which the tumor cells express EBV antigens EBNA1 and LMP2. A therapeutic vaccine comprising a recombinant vaccinia virus, MVA-EL, was designed to boost immunity to these tumor antigens. A phase I trial was conducted to demonstrate the safety and immunogenicity of MVA-EL across a range of doses. Experimental Design: Sixteen patients in the United Kingdom (UK) with EBV-positive nasopharyngeal carcinoma (NPC) received three intradermal vaccinations of MVA-EL at 3-weekly intervals at dose levels between 5 × 107 and 5 × 108 plaque-forming units (pfu). Blood samples were taken at screening, after each vaccine cycle, and during the post-vaccination period. T-cell responses were measured using IFNγ ELISpot assays with overlapping EBNA1/LMP2 peptide mixes or HLA-matched epitope peptides. Polychromatic flow cytometry was used to characterize functionally responsive T-cell populations. Results: Vaccination was generally well tolerated. Immunity increased after vaccination to at least one antigen in 8 of 14 patients (7/14, EBNA1; 6/14, LMP2), including recognition of epitopes that vary between EBV strains associated with different ethnic groups. Immunophenotypic analysis revealed that vaccination induced differentiation and functional diversification of responsive T-cell populations specific for EBNA1 and LMP2 within the CD4 and CD8 compartments, respectively. Conclusions: MVA-EL is safe and immunogenic across diverse ethnicities and thus suitable for use in trials against different EBV-positive cancers globally as well as in South-East Asia where NPC is most common. The highest dose (5 × 108 pfu) is recommended for investigation in current phase IB and II trials. Clin Cancer Res; 20(19); 5009–22. ©2014 AACR.Keywords
Other Versions
This publication has 48 references indexed in Scilit:
- Epstein-Barr Virus: An Important Vaccine Target for Cancer PreventionScience Translational Medicine, 2011
- Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4+ and CD8+ polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteinsImmunology, 2011
- SPICE: Exploration and analysis of post‐cytometric complex multivariate datasetsCytometry Part A, 2011
- A novel latent membrane 2 transcript expressed in Epstein-Barr virus–positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapyBlood, 2010
- Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal CarcinomaJournal of Immunotherapy, 2010
- Acquisition of Polyfunctionality by Epstein-Barr Virus-Specific CD8 + T Cells Correlates with Increased Resistance to Galectin-1-Mediated SuppressionJournal of Virology, 2009
- Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transferBlood, 2007
- CD4+T-Cell Responses to Epstein-Barr Virus Nuclear Antigen EBNA1 in Chinese Populations Are Highly Focused on Novel C-Terminal Domain-Derived EpitopesJournal of Virology, 2006
- CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cellsThe Journal of Experimental Medicine, 2006
- The global health burden of infection‐associated cancers in the year 2002International Journal of Cancer, 2006